伊利替康联合顺铂治疗晚期非小细胞肺癌的近期疗效及毒性反应观察  

IRINOTECAN PLUS CISPLATIN FOR THE TREATMENT OF ADVANCED NON-SMALL CELL-LUNG-CANCER

作　　者：晏军[1] 王琳[1] 魏成明[1] 刘军[1] 王东[1] 陈晓梅[1] 

机构地区：[1]四川省自贡市第一人民医院肿瘤科,自贡643000

出　　处：《现代预防医学》2010年第21期4161-4162,共2页Modern Preventive Medicine

摘　　要：[目的]观察伊立替康(CPT-11)每周给药联合顺铂(DDP)治疗晚期非小细胞肺癌(NSCLC)的近期疗效和毒性反应。[方法]42例经病理学或细胞学确诊的初治晚期NSCLC患者,接受CPT-1160mg/m2,静脉滴注,d1、8、15;DDP30mg/m2,静脉滴注,d2、3、4;28d为一周期,至少化疗2周期后评价疗效及不良反应。[结果]全组PR13例,SD27例,PD2例,总有效率30.95%。主要不良反应是粒细胞减少、恶心呕吐、腹泻。[结论]CPT-11每周给药联合DDP治疗NSCLC疗效确切,患者耐受性较好。[Objective] To evaluate the efficacy and adverse of irinotecan（CPT-11） combined with cisplatin（DDP） in the treatment of patients with advanced non-small-cell-lung-cancer（NSCLC）.[Methods] 42 previously untreated patients who were diagnosed as advanced NSCLC by pathology or cytology were enrolled.All patients were given CPT-11 60mg /m^2,ivp,d1,8,15 plus DDP 30mg /m^2,ivp,d2,3,4.The treatment period was 28 days,at least by 2 cycles of treatment,evaluated the curative effect and adverse reactions.[Results] The response rate was 30.95%,and 13 partial response,27 stable disease,2 progressive disease.The major adverse reactions were diarrhea,neutropenia,nausea and vomiting.[Conclusion] Irinotecan plus cisplatin is effective in treating patients with advanced non-small-cell-lung-cancer.And patients＇ tolerance is well.

关 键 词：晚期非小细胞肺癌 伊立替康 顺铂 

分 类 号：R735.37[医药卫生—肿瘤]